LFG
BCRX icon

Larson Financial Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Larson Financial Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.06K Buy
506
+31
+7% +$280 ﹤0.01% 2769
2026
Q1 		$4.52K Sell
475
-3,067
-87% -$23.8K ﹤0.01% 2654
2025
Q4 		$27.6K Buy
3,542
+3,267
+1,188% +$23.6K ﹤0.01% 1534
2025
Q3 		$2.09K Buy
+275
New +$2.29K ﹤0.01% 2695

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Larson Financial Group's BCRX Position: Q2 2026 in Review

Larson Financial Group increased its BioCryst Pharmaceuticals (BCRX) stake by 6.5% in Q2 2026, buying an estimated $280 and bringing the position to 506 shares worth $5.06K. The position accounts for ﹤0.01% of the portfolio, ranked #2769.

Larson Financial Group first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $27.6K in Q4 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Larson Financial Group held 506 shares of BioCryst Pharmaceuticals worth $5.06K as of Q2 2026.
  • Larson Financial Group bought 31 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $280.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2769 holding.
  • Larson Financial Group first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Larson Financial Group's BioCryst Pharmaceuticals position peaked at $27.6K in Q4 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.